Payment overview · 2025
General Payments
$759.07
49 reported records · 15 companies
Healthcare provider profile · identity verified
Joseph W Derosa
Allopathic & Osteopathic Physicians|Family Medicine · GREENVILLE, SC · NPI 1649205378
Verified facts
What the public records show
CMS Open Payments records show Joseph W Derosa received $759.07 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $297.41 | 39.2% | 25 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $93.45 | 12.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.87 | 10.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $59.58 | 7.8% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$39.21 | 5.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.40 | 4.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.08 | 3.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.82 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.07 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.90 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.02 | 2.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.66 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.38 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.70 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.52 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $759.07 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $238.34 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $177.13 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $93.45 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $59.58 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.07 | 10 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.08 | 1 | 2025 |
Source payment records
|
|||||
| Spectra WaveWriter Normalized: spectra wavewriter |
Device | Boston Scientific Corporation | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 301 | 91 |
| Lisinopril | Lisinopril | 257 | 69 |
| Omeprazole | Omeprazole | 227 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 226 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 59 |
| Losartan Potassium | Losartan Potassium | 180 | 52 |
| Simvastatin | Simvastatin | 177 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 37 |
| Alprazolam | Alprazolam | 124 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 34 |
| Lorazepam | Lorazepam | 100 | 16 |
| Metformin Hcl | Metformin Hcl | 97 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 23 |
| Metformin Hcl Er | Metformin Hcl | 94 | 29 |
| Montelukast Sodium | Montelukast Sodium | 92 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 22 |
| Ozempic | Semaglutide | 77 | 15 |
| Clonazepam | Clonazepam | 76 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 19 |
| Celecoxib | Celecoxib | 62 | 15 |
| Potassium Chloride | Potassium Chloride | 61 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 20 |
| Gabapentin | Gabapentin | 59 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Eliquis | Apixaban | 52 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 17 |
| Trazodone Hcl | Trazodone Hcl | 52 | 17 |
| Azithromycin | Azithromycin | 50 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 17 |
| Famotidine | Famotidine | 42 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | 13 |
| Furosemide | Furosemide | 39 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Prednisone | Prednisone | 34 | 23 |
| Sertraline Hcl | Sertraline Hcl | 34 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Estradiol | Estradiol | 32 | 11 |
| Carvedilol | Carvedilol | 31 | 11 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Primidone | Primidone | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Finasteride | Finasteride | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $759.07 · 49 records | ABBVIE INC. | CAPLYTA, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, INSPIRE, INTELLIS ADAPTIVESTIM, NURTEC ODT, Ozempic, PROCLAIM, QULIPTA, Rybelsus, Spectra WaveWriter, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error